DAHANCA 32研究:电化学疗法治疗复发性黏膜头颈癌
这项II期临床试验纳入26例无治愈选择的复发性头颈癌患者,在全身麻醉下进行电化学疗法,第8周CT评估肿瘤反应。5例(19%)完全缓解,10例(39%)部分缓解,客观缓解率58%,治疗期间无严重不良事件。
要点
- 复发性头颈癌患者电化学疗法客观缓解率为58%。
- 5例(19%)完全缓解,10例(39%)部分缓解。
- 治疗期间无严重不良事件,治疗后出现1例出血、2例黏膜肿胀和1例疾病进展死亡。
核心结论
- 电化学疗法对头颈癌局部复发有效,总体缓解率为58%。
研究设计与样本
- II期临床试验,纳入无治愈治疗选择的复发性头颈癌患者26例,在全身麻醉下进行电化学疗法。
主要发现
- 26例接受治疗的患者中,5例(19%)达到完全缓解,10例(39%)达到部分缓解,客观缓解率为58%。
- 两名缓解者仍无复发。
- 治疗期间无严重不良事件发生。
- 治疗后发生4起事件:1例出血、2例黏膜肿胀、1例患者因疾病进展死亡。
关键数值与推荐
- 主要终点为第8周通过CT扫描评估的肿瘤反应。
- 次要终点包括活检结果、MRI和氟脱氧葡萄糖-正电子发射断层扫描、安全性、毒性、疼痛评分和生活质量问卷。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Electrochemotherapy is an established treatment for cutaneous tumors. This study aimed at determining efficacy of electrochemotherapy in recurrent head and neck cancer. METHODS: Phase II clinical trial in patients with recurrent head and neck carcinomas with no curative treatment options. Electrochemotherapy was performed under general anesthesia. Primary endpoint was tumor response (CT scanning) evaluated at week 8. Secondary endpoints included biopsy results, MRI and fluorodeoxyglucose-positron emission tomography scanning, safety, toxicity, pain score, and quality-of-life questionnaires. RESULTS: Of 26 patients treated, 5 (19%) achieved complete response, 10 (39%) partial response, resulting in an objective response of 58%. Two responders remain without recurrence. No serious adverse events occurred during treatment. Four events occurred posttreatment: one bleeding episode, two episodes with mucosal swelling, and one patient died due to disease progression. CONCLUSION: Electrochemotherapy is efficient against local recurrence of head and neck cancer with an overall response rate of 58%.
引用
- Plaschke CC, Johannesen HH, Hansen RH, et al. The DAHANCA 32 study: Electrochemotherapy for recurrent mucosal head and neck cancer. Head Neck. 2018. PMID: 30552847. doi:10.1002/hed.25454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。